<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04194697</url>
  </required_header>
  <id_info>
    <org_study_id>4646-CL-0001</org_study_id>
    <nct_id>NCT04194697</nct_id>
  </id_info>
  <brief_title>A Study to Assess Effect of Exercise Program Provided by Smartphone Application on the Body Composition</brief_title>
  <official_title>A Study to Assess Effect of Exercise Program Provided by Smartphone Application on the Body Composition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to explore the effect of an exercise program combining&#xD;
      aerobic and resistance exercises provided by mobile healthcare applications (hereinafter&#xD;
      referred to as &quot;app&quot;) on the body composition in app-using exercise group compared to&#xD;
      non-exercise group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 25, 2019</start_date>
  <completion_date type="Actual">June 8, 2020</completion_date>
  <primary_completion_date type="Actual">June 8, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in visceral fat area</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Visceral fat area will be measured with computed tomography (CT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in body fat ratio</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Total fat ratio will be derived from body composition analyzer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subcutaneous fat area</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Subcutaneous fat area will be measured with CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total fat area</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Body fat area will be measured with CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in muscle mass</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Muscle area will be measured with body composition analyzer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in waist circumference</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Waist circumference will be measured with measuring tape.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body weight</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Body weight will be measured with body composition analyzer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events (AEs)</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>An adverse event is any untoward medical occurrence in subjects, which does not necessarily have to have a causal relationship with this study.&#xD;
An event that meets either &quot;possibly related&quot; or &quot;probably related&quot; is defined as &quot;an adverse event whose causal relationship with this study cannot be ruled out&quot; or &quot;an adverse event whose causal relationship with the exercise intervention cannot be ruled out.&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Exercise group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will conduct exercise programs provided by the app 3 times a week for 12 weeks. Except for the exercise program provided by the app, the amount of activity and exercise in daily life will not change from before the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-exercise group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will not change the amount of activity or exercise in daily life from before the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>Exercise program</description>
    <arm_group_label>Exercise group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>No exercise</intervention_name>
    <description>No exercise program</description>
    <arm_group_label>Non-exercise group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who can perform a 12-week exercise program using the specified app during the&#xD;
             study in Japan if they are assigned to the app-using exercise group.&#xD;
&#xD;
          -  Subjects who agree to perform a 12-week exercise program using the app during the&#xD;
             period specified in the protocol and not to change activities/exercise of daily living&#xD;
             compared with before participation in the study except for the exercise program using&#xD;
             the app if they are assigned to the app-using exercise group, or subjects who agree&#xD;
             not to change activities/exercise of daily living compared with before participation&#xD;
             in the study during the period specified in the protocol if they are assigned to the&#xD;
             non-exercise group.&#xD;
&#xD;
          -  Subjects with body mass index (BMI) of 25.0 kg/m^2 or more and less than 30.0 kg/m^2&#xD;
             at screening and baseline&#xD;
&#xD;
          -  Subjects with waist circumferences meeting the following at screening and baseline.&#xD;
             Male: 85 cm or more, Female: 90 cm or more&#xD;
&#xD;
          -  Female subject who applied to one of the following&#xD;
&#xD;
               -  Subjects who are postmenopausal (without a menstrual period for at least 1 year)&#xD;
                  at the time of informed consent.&#xD;
&#xD;
               -  Subjects of non-childbearing potential due to undergoing surgery.&#xD;
&#xD;
               -  Females of childbearing potential who agree to use contraception during the&#xD;
                  participation in the study and have a negative pregnancy test at screening and&#xD;
                  baseline.&#xD;
&#xD;
          -  Subjects who agree not to participate in clinical studies of drugs, regenerative&#xD;
             medicine products, or medical devices, post-marketing clinical studies, or clinical&#xD;
             research (including studies that do not use drugs, regenerative medicine products, or&#xD;
             medical devices as with this study) other than this study after providing informed&#xD;
             consent until the completion of the examination/observation at Week 12.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who regularly perform at least 1 session of exercise per week for at least 30&#xD;
             minutes per session on average other than activities of daily living during 6 months&#xD;
             before providing informed consent.&#xD;
&#xD;
          -  Subjects who receive treatment for obesity on an outpatient basis at the time of&#xD;
             informed consent or plan to start treatment for obesity on an outpatient basis during&#xD;
             the period until the completion of the examination/observation at Week 12.&#xD;
&#xD;
          -  Subjects whose systolic blood pressure (sitting position at rest) is 160 mmHg or more&#xD;
             or whose diastolic blood pressure (sitting position at rest) is 100 mmHg or more at&#xD;
             screening or baseline.&#xD;
&#xD;
          -  Subjects with concomitant uncontrolled hypertension or concomitant hypertension that&#xD;
             is considered likely to be exacerbated by the exercise intervention.&#xD;
&#xD;
          -  Subjects with previous or concomitant severe heart diseases (ischemic heart disease,&#xD;
             myocardial infarction, congestive heart failure, angina pectoris, and arrhythmia&#xD;
             requiring treatment with Î²-blockers and other drugs, etc.).&#xD;
&#xD;
          -  Subjects with previous or concomitant cerebrovascular disorders (cerebral infarction,&#xD;
             transient cerebral ischemia, etc.).&#xD;
&#xD;
          -  Subjects with fasting blood glucose of 250 mg/dL or more or with positive urinary&#xD;
             ketone bodies at screening.&#xD;
&#xD;
          -  Subjects with concomitant uncontrolled diabetes or with diabetic complications&#xD;
             (diabetic neuropathy, diabetic nephropathy, and diabetic retinopathy excluding simple&#xD;
             retinopathy).&#xD;
&#xD;
          -  Subjects with concomitant retinal neovascular lesions (exudative age-related macular&#xD;
             degeneration, retinal vein occlusion, etc.) or concomitant retinopathy occurring&#xD;
             within 6 months after laser photocoagulation.&#xD;
&#xD;
          -  Subjects with previous or concomitant arteriosclerosis obliterans of lower extremities&#xD;
&#xD;
          -  Subjects with concomitant motor disorders.&#xD;
&#xD;
          -  Subjects with concomitant severe respiratory diseases.&#xD;
&#xD;
          -  Subjects with concomitant severe liver diseases (viral hepatitis, drug-induced liver&#xD;
             injury, etc.).&#xD;
&#xD;
          -  Subjects with concomitant severe renal diseases (acute renal failure,&#xD;
             glomerulonephritis, interstitial nephritis, etc.).&#xD;
&#xD;
          -  Subjects with previous or concomitant malignancies. However, subjects are allowed to&#xD;
             be enrolled if they have experienced no recurrence without the need for treatment&#xD;
             within 5 years before providing informed consent.&#xD;
&#xD;
          -  Subjects with previous or concomitant schizophrenia, psychiatric disorders such as&#xD;
             bipolar disorder or major depressive disorder, or dementia.&#xD;
&#xD;
          -  Subjects who are taking any of the following drugs at the time of informed consent:&#xD;
             insulin preparations, sulfonyl urea hypoglycemic agents, short-acting insulin&#xD;
             secretagogues (glinide), Glucagon-like peptide (GLP)-1 receptor agonists, biguanides,&#xD;
             thiazolidines, Sodium-glucose co-transporter (SGLT)2 inhibitors, and anti-obesity&#xD;
             drugs, or subjects who plan to receive any of these drugs during the period until the&#xD;
             completion of the examination/observation at Week 12.&#xD;
&#xD;
          -  Subjects who are taking any of the following at the time of informed consent:&#xD;
             antidyslipidemic agents or drugs affecting lipid metabolism, supplements, and health&#xD;
             foods (including foods for specified health use and foods with functional claims), or&#xD;
             subjects who plan to take any of these during the period until the completion of the&#xD;
             examination/observation at Week 12. However, subjects are allowed to take these drugs,&#xD;
             supplements, or foods if they can take them with a stable dosage from at least 28 days&#xD;
             before baseline until the completion of the examination/observation at Week 12.&#xD;
&#xD;
          -  Subjects who have metal placed by lumbar spinal surgery and other surgery at the site&#xD;
             where abdominal CT scan is performed.&#xD;
&#xD;
          -  Subjects with implantable medical devices such as cardiac pacemakers and implantable&#xD;
             defibrillators.&#xD;
&#xD;
          -  Subjects who have participated or are participating in clinical studies of other&#xD;
             drugs, regenerative medicine products, or medical devices, post-marketing clinical&#xD;
             studies, or clinical research (including studies that do not use drugs, regenerative&#xD;
             medicine products, or medical devices as with this study) within 12 weeks (84 days)&#xD;
             before screening.&#xD;
&#xD;
          -  Subjects who are employed by the research implementing entity of this study or&#xD;
             institutions/organizations related to this study.&#xD;
&#xD;
          -  Subjects who are considered ineligible for the participation in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Astellas Pharma Inc.</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site JP00001</name>
      <address>
        <city>Toshima-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 9, 2019</study_first_submitted>
  <study_first_submitted_qc>December 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2019</study_first_posted>
  <last_update_submitted>May 23, 2021</last_update_submitted>
  <last_update_submitted_qc>May 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exercise program</keyword>
  <keyword>Smartphone application</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under &quot;Sponsor Specific Details for Astellas.&quot;</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

